BridgeBio Pharma, Inc.

BBIO

US10806X1028

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-06 pm EST			5-day change	1st Jan Change
65.36 ^USD	-1.22%		-1.68%	-14.55%

Mar. 06	Bridgebio Pharma Insider Sold Shares Worth $4,211,302, According to a Recent SEC Filing	MT
Mar. 04	BridgeBio Pharma, Inc. Presents Additional Data from Phase 3 Fortify Trial of BBP-418 for LGMD2I/R9	CI

BridgeBio Pharma reports Attruby product revenue $146 mln in Q4

Published on 01/12/2026 at 11:19 am EST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about BridgeBio Pharma, Inc.

Mar. 06	Bridgebio Pharma Insider Sold Shares Worth $4,211,302, According to a Recent SEC Filing	MT
Mar. 04	BridgeBio Pharma, Inc. Presents Additional Data from Phase 3 Fortify Trial of BBP-418 for LGMD2I/R9	CI
Mar. 02	Intellia gets FDA nod to resume second gene therapy trial after safety pause	RE
Feb. 27	Ascendis wins US approval for therapy for children with dwarfism	RE
Feb. 25	Oppenheimer Adjusts Price Target on BridgeBio Pharma to $81 From $83, Maintains Outperform Rating	MT
Feb. 25	Morgan Stanley Lifts Price Target on BridgeBio Pharma to $98 From $96, Keeps Overweight Rating	MT
Feb. 25	Analyst recommendations: IBM, Axon, Caterpillar, Fair Isaac, Gilead…
Feb. 24	BridgeBio Pharma, Inc., Q4 2025 Earnings Call, Feb 24, 2026
Feb. 24	BridgeBio Pharma Q4 Loss Narrows, Revenue Rises	MT
Feb. 24	Earnings Flash (BBIO) BridgeBio Pharma Posts Q4 Loss $1, vs. FactSet Est of $0.71 Loss	MT
Feb. 24	Earnings Flash (BBIO) BridgeBio Pharma, Inc. Reports Q4 Revenue $154.2M, vs. FactSet Est of $146.8M	MT
Feb. 24	BridgeBio Pharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Feb. 19	BridgeBio Pharma Insider Sold Shares Worth $754,557, According to a Recent SEC Filing	MT
Feb. 13	Oppenheimer Adjusts BridgeBio Pharma Price Target to $83 From $81, Maintains Outperform Rating	MT
Feb. 12	BridgeBio Pharma, Inc. - Special Call

BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.

Employees

837

Sector

Pharmaceuticals

More about the company